Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Baxter
Express Scripts
McKinsey
AstraZeneca

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

OPTISON Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Optison, and when can generic versions of Optison launch?

Optison is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-seven countries.

The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.

Drug patent expirations by year for OPTISON
Drug Prices for OPTISON

See drug prices for OPTISON

Generic Entry Opportunity Date for OPTISON
Generic Entry Date for OPTISON*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OPTISON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Chiltern International Inc.Phase 4
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityEarly Phase 1
National Cancer Institute (NCI)Early Phase 1

See all OPTISON clinical trials

Pharmacology for OPTISON
Synonyms for OPTISON
1,1,1,2,2,3,3,3-Octafluoropropane
1,1,1,2,2,3,3,3-octakis(fluoranyl)propane
218599-63-4
300408-51-9
76-19-7
A838638
AC1L1MIR
AC1Q4IBX
AKOS006228213
AN-23892
AN-37829
C-50894
C3F8
C3F8-gas
CHEBI:31980
CHEMBL1663
CK0N3WH0SR
CTK5E2580
D01738
DB-056033
DB00556
Definity
Definity (TN)
DMP 115
DMP-115
DTXSID9052503
EC 200-941-9
EINECS 200-941-9
FC 218
FC 218 (refrigerant)
FCH918400
Flutec PP30
Freon 218
FS-069
FS069
FT-0621948
FT-0631321
Genetron 218
HFC 218
HSDB 8074
I14-14876
KB-59511
liposome-encapsulated perfluoropane microsphere
LS-120891
MRX 115
MRX-115
OCTAFLUOROPROPANE
octafluoropropane-lipid microsphere
Octafluoropropaneor Refrigerant gas R 218
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluoropropaneor Refrigerant gas R 218 [UN2424] [Nonflammable gas]
Octafluorpropan
Oktafluorpropan
Optison (Salt/Mix)
Perfluoropropane
Perfluoropropane (PFC-218) 99.9%
Perfluoropropane 99+%
Perfluoropropaneminimum
Perflutren
Perflutren (JAN/USAN/INN)
Perflutren [USAN:INN:BAN]
Perflutren [USAN]
Perflutren and Human Albumin
Perflutren Lipid Microsphere
Perflutren lipid microspheres
Perflutren Protein-Type A Microspheres injection
Perflutren-lipid microsphere
PFC 218
Propane, 1,1,1,2,2,3,3,3-octafluoro-
Propane, octafluoro-
Propane,1,1,1,2,2,3,3,3-octafluoro-
QYSGYZVSCZSLHT-UHFFFAOYSA-N
R 218
RC 218, PFC 218
SBB090673
UN 2424
UN2424
UNII-CK0N3WH0SR
YM454
ZINC8214651
ZX-AP010865

US Patents and Regulatory Information for OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for OPTISON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997   Start Trial   Start Trial
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997   Start Trial   Start Trial
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for OPTISON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1853250 122014000065 Germany   Start Trial PRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
1853250 238 50005-2014 Slovakia   Start Trial PRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230
1853250 CA 2014 00034 Denmark   Start Trial PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
1853250 37/2014 Austria   Start Trial PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
0961612 09C0050 France   Start Trial PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111
0961612 C00961612/01 Switzerland   Start Trial PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014
0961612 300417 Netherlands   Start Trial PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080114
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Johnson and Johnson
Mallinckrodt
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.